4 Hot Analyst Reads For Friday, July 20th
“My husband and I have never considered divorce... murder sometimes, but never divorce.” ― Joyce Brothers
Sign Up Free Today: To comment on this article or to get and read these full articles free every day before the market open to your ‘in box’ as published, just hit the + Follow button in the upper right-hand corner of this site.
Here are four small cap stocks seeing notable analyst commentary just before we open for the last trading day of the week
Citigroup is raising their price target on Repligen (RGEN) to $56 from $45 previously while maintaining their Buy rating on this concern with a ~$2 billion market cap. Citi's analyst notes that "the company's momentum can continue as it pushes further into a healthy bioproduction end market with an improved portfolio." He also believes Repligen shares have a "solid runway and good upside potential."
Given the shares trade near $50 already, the upward revision would seem necessary to keep a Buy rating on the stock.
SunTrust Robinson initiatesViking Therapeutics (VKTX) as a new Buy with a $14 price target before the bell today. Here is the synopsis behind the rating change
'The company's VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non- alcoholic steatohepatitis disease, or NASH. In addition, VK2809 demonstrated a significant reduction in multiple lipid parameters in phase 1b trials, and the analyst also notes that the stock is trading at a significant discount relative to other companies targeting NASH.'
The stock has already quadrupled since we gave it a 'thumbs up' last October.
Author's Note:To get our free research articles on attractive biotech and pharma stocks as soon as they are published from our SeekingAlpha handle, just clickherefor our profile. Hit the big orange "Follow" button and choose the real-time alerts option.
Mirati Therapeutics (MRTX) sees its price target raised to $63 from $42 this morning at H.C. Wainwright this morning as their analyst reiterates his buy rating and sees a 'higher probability of success for sitravatinib' . The analyst 'now applies a 45% probability of success for sitravatinib monotherapy and projects revenues of $407M, $448M and $179M for sitravatinib in combination with checkpoint therapy, sitravatinib as a single agent and mocetinostat, respectively'.
We also told you about this name over at SeekingAlpha almost exactly one year ago when the shares traded right at $5 a share.
Finally, Cantor Fitzgerald reissued their Outperform rating on small cap Cerus (CERS) yesterday but they raised their price target to $9 from $7 previously. Cantor's analyst notes that the company has "various growth drivers for the next several years". He also believes 'the FDA is moving closer to providing final guidance for methods to reduce bacterial contamination in transfused platelets, and Cerus' pathogen-inactivation technology should be included.'
And those are four small cap concerns seeing recent analyst activity before the market opens this Friday. Happy Hunting.
New Free Report Available: My colleagues at Investors Alley have just published a free report entitled '10 Simple Rules To Trade Options Like A Pro' for those that want to learn more about profitably adding options strategies to their investing 'toolbox' including Buy-Writes on many of the small caps we cover in these pieces, it is now available free via download HERE.